开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2024-06-15 ms6000001420425005 来自北京

In press多久会校稿啊？已经3周了

97 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2022-12-03 我真爱学习来自浙江省

同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。
另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！

131 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2024-06-15 ms6000001420425005 来自北京

请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知

88 0

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2024-02-26 ms4000000361701675 来自广西

偏重的研究方向：肿瘤学;肿瘤;生信分析
经验分享：这个杂志已经不是预警期刊，时间快

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2023-10-23 1501fa70a6m

这个竟然没有doi 感觉不太靠谱哎

107 0

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2023-07-28 阿木好拽哦来自江西省

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。

121 0

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2023-01-17 158200a639m 来自富山县

还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投

164 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2023-04-18 小红帽起飞来自广西

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤学;肿瘤
经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了

136 0

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2022-09-18 shademei

偏重的研究方向：肿瘤
经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库

167 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2210010, encodeId=5c7322100105a, content=In press多久会校稿啊？已经3周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:44:47 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104172, encodeId=f70421041e2a4, content=同志们，这个编辑让我润色，润色公司是江苏的，我也是醉了。这是国人主编，还是有合作啊？同时我想问问润色后接受度高不高？花了钱不接受不是很痛苦。 另外纯META关于肿瘤药物的有没有推荐的杂志啊？感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=004b5567409, createdName=我真爱学习, createdTime=Sat Dec 03 23:03:34 CST 2022, time=2022-12-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2210011, encodeId=7ab42210011d5, content=请问各位，In press 状态多久之后才会校稿，我已经缴完费，状态变为in press3周了，还没收到校稿通知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddb25627694, createdName=ms6000001420425005, createdTime=Sat Jun 15 10:48:33 CST 2024, time=2024-06-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2189445, encodeId=8553218944545, content=偏重的研究方向：肿瘤学;肿瘤;生信分析 经验分享：这个杂志已经不是预警期刊，时间快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231027/c966878f146e4e0dbf8418b9b86fbb57/c2d7036599894bf0b8f0dd9085325554.jpg, createdBy=54379018170, createdName=ms4000000361701675, createdTime=Mon Feb 26 12:19:19 CST 2024, time=2024-02-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2164384, encodeId=a8b52164384fd, content=这个竟然没有doi 感觉不太靠谱哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/eb5a865268a68b18f8ab32e0182c970d.jpg, createdBy=da112119856, createdName=1501fa70a6m, createdTime=Mon Oct 23 13:03:11 CST 2023, time=2023-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150269, encodeId=e2a2215026940, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：时间还是比较久的，花了5个月。不太好的就是录用影响因子还在3.9，不到一个月就变成了2.2 不过就这样吧，人要学会知足，能中就好，文章本身也没花太多心血，reviewers和editor也没太多难改的意见，大多都是格式问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c15b5396861, createdName=阿木好拽哦, createdTime=Fri Jul 28 15:57:30 CST 2023, time=2023-07-28, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2110561, encodeId=5ca72110561c7, content=还在投稿的，我建议撤稿吧，我已经看到了最新一期的预警期刊，这个期刊是高风险期刊，在月底会公布，慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed8d2149644, createdName=158200a639m, createdTime=Tue Jan 17 12:25:51 CST 2023, time=2023-01-17, status=1, ipAttribution=富山县), GetPortalCommentsPageByObjectIdResponse(id=2126748, encodeId=f9c12126e48bc, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学;肿瘤 经验分享：期刊还是要求，伦理，润色，返修意见还是很多的，辛好录用了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220712/73e5adb12e9542ba82e0cdedcb6f7d85/9147fd82fb334746850dda7ccd06a4c9.jpg, createdBy=fab48234685, createdName=小红帽起飞, createdTime=Tue Apr 18 14:09:40 CST 2023, time=2023-04-18, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1250370, encodeId=0c4c12503e012, content=偏重的研究方向：肿瘤 经验分享：这个杂志怎么给了小修连个邮件也不发，今天在投稿界面刚看见，3分以上值得拥有，做的胃癌全胃切除的nomo,.用的本院数据库, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=shademei, createdTime=Sun Sep 18 00:31:12 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113527, encodeId=b81a211352e11, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信分析 经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6858365730, createdName=ms5000001207401255, createdTime=Tue Feb 07 20:36:28 CST 2023, time=2023-02-07, status=1, ipAttribution=广西)]

2023-02-07 ms5000001207401255 来自广西

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤;生信分析
经验分享：2023年还是别投了，IF20年4.06,21年3.94，22年1.96，就没见过那么骚的杂志。不如Oncology Letters还有Oncology Reports

142 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务